Zanolimumab: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) Sourced trade name HuMax-CD4 |
Anypodetos (talk | contribs) →References: Page already in Cat:Monoclonal antibody stubs using AWB |
||
| Line 34: | Line 34: | ||
{{humanmonoclonals}} |
{{humanmonoclonals}} |
||
[[Category:Monoclonal antibodies]] |
|||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||
Revision as of 16:43, 30 November 2009
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Molar mass | 147 kDa |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, cutaneous and peripheral T-cell lymphoma.[2][3]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |